Skip to main content

Advertisement

SpringerLink
Log in

Inhibitory effect of Hypoxia inducible factor-1 antisense oligonucleotide on growth of human hepatocellular carcinoma cells

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Object

To observe the inhibitory effect of Hypoxia inducible factor-1 antisense oligonuclecotide on growth of human hepatocellular carcinoma cells and gene expression of HIF-1, in order to seek a new gene therapy for hepatocellular carcinoma.

Methods

Six Hypoxia inducible factor-1 antisense oligonuclecotides with various concentrations (0.2 μmol/l, 0.4 μmol/l, and 0.8 μmol/l) were transformed into HepG2 cells by lipofectamine reagent. 72 h after transfection, MTS assay was used to detect cellular proliferation. In addition, Hypoxia inducible factor-1 antisense oligonuclecotide2 with various concentrations (0.2, 0.4, 0.8, and 1.0 μmol/l) were transformed into HepG2 cells. About 48 h after transfection, reverse transcription-polymerase chain reaction assay and Western Blot assay were employed to detect the expression of Hypoxia inducible factor-1 gene and the synthesis of Hypoxia inducible factor-1 protein respectively.

Results

HepG2 cell growth was inhibited by 6 Hypoxia inducible factor-1 antisense oligonuclecotides at various concentrations. Among them, Hypoxia inducible factor-1 antisense oligonuclecotide2 showed the most effective inhibition ability (P < 0.01), the inhibitory rate was 89.66% at the concentration of 1.0 μmol/l. About 48 h after transfection, Hypoxia inducible factor-1 mRNA expression was downregulated and Hypoxia inducible factor-1 protein synthesis was decreased by antisense oligonuclecotide2.

Conclusions

The hepatocellular carcinoma cell proliferation was inhibited by Hypoxia inducible factor-1 antisense oligonuclecotide. Moreover, the gene expression and protein synthesis of Hypoxia inducible factor-1 were reduced by Hypoxia inducible factor-1 antisense oligonuclecotide. The findings suggested that antisense technique targeting Hypoxia inducible factor-1 might be an effective gene therapy of human hepatocellular carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93(4):266–76.

    Article  PubMed  Google Scholar 

  2. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004;5(5):343–54.

    Article  PubMed  CAS  Google Scholar 

  3. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3(10):721–32.

    Article  PubMed  CAS  Google Scholar 

  4. Belozerov VE, Van Meir EG. Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 2005;16(9):901–909.

    Article  PubMed  CAS  Google Scholar 

  5. Aboul-Fadl T. Antisense oligonucleotides: the state of the art. Curr Med Chem 2005;12(19):2193–214.

    Article  PubMed  CAS  Google Scholar 

  6. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005;5(6):468–79.

    Article  PubMed  CAS  Google Scholar 

  7. Peyman A, Helsberg M, et al. Inhibition of viral growth by antisense oligonucleotides directed against the IE110 and the UL30 mRNA of herpes simplex virus type-1. Biol Chem Hoppe Seyler 1995;376(3):195–8.

    PubMed  CAS  Google Scholar 

  8. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 1996;2(6):668–75.

    Article  PubMed  CAS  Google Scholar 

  9. Brahimi-Horn MC, Pouysségur J. The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol 2005;242:157–213.

    Article  PubMed  CAS  Google Scholar 

  10. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9(6):677–84.

    Article  PubMed  CAS  Google Scholar 

  11. Zagzag D, Zhong H, Scaizitti JM, et al. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 2000;88(11):2606–18.

    Article  PubMed  CAS  Google Scholar 

  12. Akakura N, Kobayashi M, Horiuchi I, et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001;61(17):6548–54.

    PubMed  CAS  Google Scholar 

  13. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60(6):1541–5.

    PubMed  CAS  Google Scholar 

  14. Zhang Q, Zhang ZF, Rao JY, et al. Treatment with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinomas. Int J Cancer 2004;111(6):849–57.

    Article  PubMed  CAS  Google Scholar 

  15. Zhang W, Zhang H, Xing L. Antisense oligonucleotide of hypoxia-inducible factor-1alpha suppresses growth and tumorigenicity of lung cancer cells A549. J Huazhong Univ Sci Technolog Med Sci 2006;26(4):448–50.

    Article  PubMed  CAS  Google Scholar 

  16. Ding L, Chen X, Jing K, Wang H, Zhang W. Inhibition of the VEGF expression and cell growth in hepatocellular carcinoma by blocking HIF-1alpha and Smad3 binding site in VEGF promoter. J Huazhong Univ Sci Technolog Med Sci 2006;26(1):75–8.

    Article  PubMed  CAS  Google Scholar 

  17. Vaupel P, Mayer A. Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol 2005;12(1):5–l0.

    Article  PubMed  Google Scholar 

  18. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy. Oncologist 2004;9(5):31–40.

    Article  PubMed  Google Scholar 

  19. Ji Z, Yang G, Susan S, et al. Induction of hypoxia-inducible factor-1alpha overexpression by cobalt chloride enhances cellular resistance to photodynamic therapy. Cancer Letters 2006;244(2):182–9.

    Article  PubMed  CAS  Google Scholar 

  20. Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor-1. Cancer Res 2003;63(5):1138–43.

    PubMed  CAS  Google Scholar 

  21. Pennachietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3(4):347–61.

    Article  CAS  Google Scholar 

  22. Birner P, Schindi M, Obermair A, et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60(17):4693–6.

    PubMed  CAS  Google Scholar 

  23. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001;7(6):1661–8.

    PubMed  CAS  Google Scholar 

  24. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001;93(4):309–14.

    Article  PubMed  CAS  Google Scholar 

  25. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61(7):2911–6.

    PubMed  CAS  Google Scholar 

  26. Koukourakis MI, Giatromanolaki A, Skarlatos J, et al. Hypoxia inducible factor (HIF-1α and HIF-2α) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 2001;61(5):1830–2.

    PubMed  CAS  Google Scholar 

  27. Powis G, Kirkpatrick L. Hypoxia inducible factor-1α as a cancer drug target. Mol Cancer Ther 2004;3(5):647–54.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The health department of Zhejiang Province, China, funded the study.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, First Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, 310003, China

    Chen WeiXing, Hu Tiantian, Ni Qun, Yu Chaohui & Xu Ping

Authors
  1. Chen WeiXing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hu Tiantian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ni Qun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu Chaohui
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xu Ping
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xu Ping.

Rights and permissions

Reprints and permissions

About this article

Cite this article

WeiXing, C., Tiantian, H., Qun, N. et al. Inhibitory effect of Hypoxia inducible factor-1 antisense oligonucleotide on growth of human hepatocellular carcinoma cells. Med Oncol 25, 88–92 (2008). https://doi.org/10.1007/s12032-007-0050-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-007-0050-8

Keywords

Search

Navigation